Precipio Successfully Completes Nasdaq Hearing Process
May 03 2019 - 9:10AM
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO),
announced that yesterday, in accordance with established Nasdaq
protocol, the company held a hearing regarding its recent steps
undertaken by it in order to regain compliance with the minimum bid
price of $1.00.
Members of the Nasdaq Panel discussed the
company’s situation with Precipio’s management team, and concluded
that, upon completion of the number of remaining trading days above
the $1 bid price, the company shall notify the committee in writing
that it has satisfied the requirements under Nasdaq’s
rules.
“I am delighted to put this issue behind us. The
company presented a solid business plan before the Panel with
strong growth prospects indicating to the Panel that we believe
these measures will enable our share price to meet the requirements
necessary to remain listed on the Nasdaq,” said Ilan Danieli,
Precipio’s CEO. “We can now focus our energy on the continued
growth of the company and delivering on our mission”.
About Precipio
Precipio has built a platform designed to
eradicate the problem of misdiagnosis by harnessing the intellect,
expertise and technology developed within academic institutions and
delivering quality diagnostic information to physicians and their
patients worldwide. Through its collaborations with world-class
academic institutions specializing in cancer research, diagnostics
and treatment such as the Yale School of Medicine and Harvard’s
Dana-Farber Cancer Institute, Precipio offers a new standard of
diagnostic accuracy enabling the highest level of patient care. For
more information, please visit www.precipiodx.com.
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements,” within the meaning of federal
securities laws including financial projections related thereto and
potential market opportunity, plans and prospects and other
statements containing the words “anticipate,” “intend,” “may,”
“plan,” “predict,” “will,” “would,” “could,” “should,” and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
The Company's actual results could differ materially from those
anticipated in these forward-looking statements as a result of
various factors. Factors that could cause future results to
materially differ from the recent results or those projected in
forward-looking statements include the known risks, uncertainties
and other factors described in the Definitive Proxy filed by the
Company on April 29, 2019 and the Company’s Annual Report on Form
10-K for the year ended December 31, 2018 as filed on April 16,
2019 as well as the Company’s prior filings and from time to time
in the Company’s subsequent filings with the Securities and
Exchange Commission. Any change in such factors, risks and
uncertainties may cause the actual results, events and performance
to differ materially from those referred to in such statements. All
information in this press release is as of the date of the release
and the Company does not undertake any duty to update this
information, including any forward-looking statements, unless
required by law.
Inquiries:
investors@precipiodx.com
+1-203-787-7888
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Sep 2023 to Sep 2024